CMS concentrates on innovative products that are global first-in-class or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems, and has established an innovative pipeline with relatively high innovation level, good market potential and competitive differentiation advantages.

CMS has been deeply engaged in the field of skin health for many years, and has deployed a number of dermatology products with competitive differentiation advantages, such as Hirudoid (existing exclusive product), Tildrakizumab (innovative drug at the registration trial stage in China); meanwhile, the Group has accumulated abundant sales and promotion resources in the dermatology field. As at 31 December 2020, the Group's sales and promotion network has covered about 57,000 hospitals and medical institutions, over 200,000 retail pharmacies, and about 12,000 dermatologists, and has approximately 700 professional dermatology promotion staff. In order to effectively utilize the sales and promotion channel resources and improve the efficiency in the dermatology field, the Group acquired Luqa Ventures (Luqa), a dermatology specialty company, on 1 February 2021, which has enriched the Group’s dermatology line and expanded the Group’s business boundary with its strengths to enter the medical aesthetic field.

Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.